Jiangsu NHWA Pharmaceutical (002262.SZ) announced on November 5th that its subsidiary Jiangsu Yuanheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Yuanheng Pharmaceutical") recently obtained the "Drug Registration Certificate" for the chemical drug Dorzolamide Sodium Eye Drops approved and issued by the National Medical Products Administration.
Dorzolamide Sodium Eye Drops are suitable for dry eye patients with corneal epithelial damage accompanied by abnormal tears. By acting on the conjunctival tissue and P2Y2 receptors on cup-shaped cell membranes, the intracellular calcium ion concentration increases, promoting the secretion of tears containing water and mucin, making the tear layer close to a normal state in terms of quality and quantity, thereby improving corneal epithelial damage.
